What is the evidence of EPA-based therapy for CV prevention?10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Ankara, Turkey - Online CME
Video navigation menu
- Effect of EPA on atherosclerotic plaques 1:02
- Low dose omega-3 FAs provide no CV benefit 2:15
- An overview of CV outcomes trials with omega-3 FAs 2:55
- How can the different outcomes be explained? 9:28
This lecture by Lale Tokgözoğlu was part of an accredited symposium "Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides" held during the virtual ESC Congress 2021.
Prof. Lale Tokgözoğlu, MD, is Professor of Cardiology at Hacettepe University, Ankara, Turkey.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Amarin.
This is available as accredited online CME for members. Click the button below to enroll:Enroll
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: